Article Information
History
- February 19, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Takuya Tada1,
- Belinda M. Dcosta1,
- Hao Zhou1,
- Ada Vaill2,
- Wes Kazmierski2 and
- Nathaniel R. Landau1,3,*
- 1Department of Microbiology, NYU Grossman School of Medicine, New York, NY 10016, USA
- 2Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510, USA
- ↵*Correspondence: nathaniel.landau{at}med.nyu.edu, Nathaniel R. Landau, Ph.D. NYU Langone Medical Center, 430 East 29th Street, Alexandria West Building, Rm 509, New York, NY 10016, Phone: (212) 263-9197, Email: nathaniel.landau{at}med.nyu.edu
Posted February 19, 2021.
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
